Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
KZIA
Stock Latest News
Ratings
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Developments in Cancer Treatment
7d ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib
9d ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics’ paxalisib monotherapy shows tumor cell cluster disruption
9d ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Secures $2 Million in Private Placement to Advance Oncology Programs
2M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics announces $2M private placement
2M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Announces At the Market Offering Agreement
2M ago
6K
KZIA
Premium
Ratings
Promising Clinical Developments and Financial Adjustments Drive Buy Rating for Kazia Therapeutics
2M ago
KZIA
Premium
The Fly
Kazia Therapeutics target adjusted to $13 from $2 at H.C. Wainwright
2M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Announces Promising Early Results in Breast Cancer Trial
2M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics reports preliminary results from Phase 1b trial
2M ago
KZIA
Premium
The Fly
Kazia Therapeutics trading halted, volatility trading pause
3M ago
KZIA
Premium
The Fly
Kazia Therapeutics trading resumes
3M ago
KZIA
Premium
Ratings
Buy Rating for Kazia Therapeutics Driven by Promising Paxalisib Data and Strategic Developments
3M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Unveils Promising Preclinical Data for Paxalisib in Breast Cancer
3M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics trading resumes
3M ago
KZIA
Premium
The Fly
Kazia Therapeutics trading halted, volatility trading pause
3M ago
KZIA
Premium
The Fly
Kazia Therapeutics announces publication of preclinical research on paxalisib
3M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development
3M ago
6K
KZIA
Premium
Ratings
Kazia Therapeutics: Strategic Advancements and Market Opportunities Reinforce Buy Rating
4M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Initiates Phase 1b Trial of Paxalisib in Advanced Breast Cancer
4M ago
6K
KZIA
Premium
The Fly
Kazia Therapeutics says first patient dosed in Phase 1b Trial of paxalisib
4M ago
KZIA
Premium
Company Announcements
Kazia Therapeutics Re-elects Director Robert Apple at AGM
4M ago
6K
KZIA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
